Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Cash Helps Boost Xoma’s 2007 Revenue

This article was originally published in The Pink Sheet Daily

Executive Summary

Position is strong as type 2 diabetes candidate advances.

You may also be interested in...



Regeneron’s Ultra-Orphan Arcalyst Hits The Market With A Rare Price

$250,000 per year wholesale acquisition cost to treat rare genetic disorder, firm tells “The Pink Sheet” DAILY.

Xoma’s New Business Strategy Emphasizes Proprietary Pipeline

Antibody developer’s near-term focus is on advancing its anti-inflammatory agent 052 and antimicrobial peptide 629 and partnering Neuprex.

Xoma Launches Phase I Trial Of Monoclonal Antibody Diabetes Therapy

Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel